{
  "trial_id": "NCT03961763",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "www.randomization.com",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Participants were informed informally via telephone first, and then invited to the Clinic by a Patient Invitation Letter.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "A structured one-to-one information session was carried out with each participant at the Clinic, during which they were given a Participant Information Sheet.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Participants provided written informed consent by signing the a Participant Consent Form.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Total sample size was 44, consisting of two 22-subject groups (control and intervention group).",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "A targeted sample size of 36 subjects (18 per arm) was expected to provide at least 80% power to detect a difference of 5% or above in primary outcome non-HDL-C and LDL-C III particle concentration when compared with placebo (\u03b1=0.05).",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Sample size was assigned as 44 to allow for subject attrition and other potential causes of study withdrawal up to 20%.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "The power calculation was based on the mean changes in non-HDL-C measurement of the previous COMBOS trial which is a largest randomized placebo controlled trial that has the same design with this study.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "A randomized, double-blind, placebo controlled, parallel groups study was carried out.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Before entry into the intervention phase of the study, 8-weeks of dietary lead-in was carried out.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Study participants received dietary counselling for the 8 weeks before the intervention, based on the heart-healthy diet structured in the United Kingdom (UK) National Institute of Health Care Excellence (NICE) guidelines (2014).",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Adherence to dietary advice was also measured by a 3-day weighed intake food diary at Week 4.",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Current use of n-3 supplements",
      "label": "does_not_trigger",
      "evidence": "none"
    },
    {
      "criterion": "Recent history of certain heart, kidney, liver, or cancer: Patients that have had any type of heart surgery, Patients that are diagnosed with any type of cancer and/or have had any kind of cancer therapy, Patients that have had kidney failure, Patients that have had liver failure, in the past 6 months",
      "label": "triggers",
      "evidence": "quote"
    },
    {
      "criterion": "Pregnant or lactating females",
      "label": "does_not_trigger",
      "evidence": "none"
    }
  ],
  "notes": "The patient is a 32-year-old obese woman who came to the clinic with weight concerns. She is complaining of sleep apnea, PCO and dissatisfaction with her body shape.",
  "_meta": {
    "topic_id": "36",
    "trial_id": "NCT03961763",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}